$WAT

WATERS CORP /DE/ (WAT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

WATERS CORP /DE/ (WAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On August 17, 2026, Robert L. Carpio III notified Waters Corporation (the “Company”) of his decision to resign from his

Original reporting
Published Aug 21, 2026, 1:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 1:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$WAT
Neutral
medium confidence
Mentioned
$WAT
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$WATNeutralLow
01

Why it matters

The filing provides the first public notice of the leadership change, offering a factual update but no immediate catalyst for price movement.

02

Market read

A routine executive transition with limited immediate market impact.

03

What to watch

Potential hidden strategic initiatives under the new leadership that are not disclosed in the filing.

Relevance 6/10Novelty 6/10Timing: today

Background

SEC Form 8‑K filed by Waters Corporation reporting a senior executive resignation and a new appointment.

Company-level read

Ticker impact

$WATNeutralMedium confidence
Context

Senior Vice President Robert L. Carpio III resigned and Tina Wu was appointed to lead the Analytical Sciences Division.

Expected impact

minimal to no immediate price movement

Evidence & confidence

The change is a routine leadership transition without disclosed financial impact or strategic shift.

Market effects

Limited; Waters operates in analytical instruments, and the change does not signal broader sector trends.

None; the filing is company‑specific to the U.S. market.

Low; no cross‑border implications.

Counterpoint

If the new SVP accelerates product rollout, the stock could see upside beyond the neutral expectation.

Key entities

  • Waters Corporation

    Provider of analytical instruments and software.

  • Robert L. Carpio III

    Departing Senior Vice President, Waters Analytical Sciences Division.

  • Tina Wu

    Appointed Senior Vice President, Waters Analytical Sciences Division.

Related articles

$WATHighAI 8/10

Is Wall Street Bullish or Bearish on Waters Corporation Stock?

Waters Corporation (WAT), a $40.7B life sciences and diagnostics company, reported Q2 2026 adjusted EPS of $3.05 and revenue of $1.65B, exceeding expectations. The stock has risen 43% over 52 weeks, outperforming the S&P 500. Analysts expect 10.9% EPS growth for 2026, with a consensus 'Moderate Buy' rating and a mean price target of $438.43.

$WATMed

WAT Upgraded by Piper Sandler -- Price Target Raised to $480

Piper Sandler upgraded Waters Corporation (WAT) to Overweight, raising its price target to $480 from $400. The company's stock is currently trading at $423.22, slightly above its GF Value™ of $411.65, indicating a 2.8% overvaluation. Waters Corporation has a GF Score™ of 95/100, reflecting strong growth and momentum but moderate financial strength. Insider activity shows recent selling of $1,442,930 worth of shares.

$WATHighAI 9/10

Waters (WAT) Q2 2026 Earnings Call Transcript

Waters (WAT) reported Q2 2026 revenue of $1.645 billion, above the top of guidance, with 9% organic growth and adjusted EPS of $3.05. Full-year 2026 guidance was raised to 7% to 9% organic revenue growth and adjusted EPS of $14.45 to $14.65. Management cited cost actions, FX headwinds, China DRG headwinds, and progress in acquired biosciences and diagnostics.

$WATMedAI 8/10

Waters Q2 Earnings Call Highlights

Waters (NYSE:WAT) reported Q2 updates from its earnings call. Materials Science Division revenue rose to $87M. Biosciences and Diagnostic Solutions acquired from BD generated $817M revenue. Waters raised FY organic constant-currency growth outlook to 7% to 9%, projecting FY reported revenue of $3.370B to $3.431B and adjusted EPS of $14.45 to $14.65.